Opdivo (nivolumab) - Ono Pharmaceutical, BMS
cyclophosphamide - Generic mfg.
Keytruda (pembrolizumab) - Merck (MSD)
PD-1 Pathway Inhibition: Potential Trigger of Anti-GBM Glomerulonephritis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0751; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 52-year-old female with metastatic melanoma was initially treated with Pembrolizumab before transitioning to Nivolumab due to recurrence...The patient was started on dialysis, daily plasma exchange, IV pulse steroids, and cyclophosphamide...National Comprehensive Cancer Network. Updated 2025-10-2" 
Glioblastoma • Glomerulonephritis • Immunology • Lung Cancer • Lupus Nephritis • Melanoma • Nephrology • Pneumonia • Solid Tumor • Vasculitis
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4558780
 
Rachel L. Fine; Mohamed Ahmed Younis; Tyler Sims; Sadiq Ahmed
 
Oct 2, 2026
 
Prev Next